Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study

Aortic Valve Stenosis Clinical Trial

— ARISTOTE  

Official title:

Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03315832
• Other study ID #: I16007 (ARISTOTE)
• Status: Withdrawn
• Phase: Phase 2/Phase 3
• Start date: January 2, 2023
• Est. completion date: July 2, 2025

Study information

• Verified date: March 2023
• Source: University Hospital, Limoges
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aortic stenosis (AS) is the most frequent valvular heart disease in Western countries, with increasing prevalence. Recent guidelines recommend aortic valve intervention (surgical aortic valve replacement [SAVR] or transcatheter aortic valve replacement [TAVR]) in severe AS, as soon as symptoms or left ventricular (LV) dysfunction occur, in order to improve clinical outcome and achieve LV mass (LVM) regression. The highest amount of LVM regression is obtained during the first year. Nevertheless, there is heterogeneity in LV remodeling and residual LV hypertrophy is associated with poorer postoperative improvement in cardiac function and morphology. Incomplete regression of LV hypertrophy at 12 months after SAVR is a powerful predictor of adverse outcome. Yet, the use of specific pharmacological therapy to improve postoperative LVM regression could be an appealing therapeutic option after aortic valve intervention.

Renin-angiotensin-aldosterone system blockers (RAASb) and more particularly angiotensin-II receptor blockers (ARBs) are efficient in reducing LVM in hypertensive patients, as emphasized by several meta-analyses. In addition, ARBs improve myocardial relaxation, diastolic function, decreased hypertrophy and may have anti-fibrotic effects. In a recent retrospective study from our group, RAASb prescription after SAVR was associated with increased survival, but confirmation through a randomized trial is mandatory. In a prospective randomized single-center study, the use of candesartan was associated both with LV and LA remodeling as compared to the conventional management. Nevertheless, these results are based on echocardiographic data, which is not the gold standard for the assessment cardiac remodeling, and no placebo or active comparator was tested to control the impact of ARBs in these patients.

The primary objective of this Phase II study is to investigate the efficacy of valsartan, introduced postoperatively, as compared to placebo, on 1-year changes in indexed LVM, as assessed by CMR, in patients undergoing aortic valve intervention (SAVR or TAVR) for AS.

The secondary objectives are to compare the efficacy of valsartan vs. placebo in terms of one-year changes (difference from baseline) in cardiac function and in cardiac morphology, one-year exercise capacity and one-year changes in biomarkers related to cardiac function. In addition, the assessment of the safety of valsartan will also be considered as secondary objective.

The ARISTOTE trial is a multicenter prospective phase II, randomized, double-blind study including patients with the diagnosis of severe AS and indication for valve intervention.

The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist.

Patients will be randomized between 2 groups (valsartan versus placebo) and the treatment will be initiated (80 mg daily) at 5±4 days following aortic valve intervention. The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.

The patients will be cautiously monitored and any adverse events will be collected. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study. The tolerance will be regularly assessed and dose adjusted according to a pre-specified algorithm.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2, 2025
• Est. primary completion date: July 2, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men with age =18 years

• Women at postmenopausal state as defined by absence of menses for the last 12 months without alternative medical cause.

• Severe AS, defined according most recent guidelines (aortic valve area <1.0cm² or <0.6cm²/m² and aortic mean pressure gradient =40mmHg or aortic maximal velocity >4m/s, as assessed using transthoracic echocardiography [TTE]).

• Indication for aortic valve intervention

• Affiliation to the French Social Security system

• Signed informed consent.

Exclusion Criteria:

• Patients already under any Renin-Angiotensin-Aldosterone System blockers (RAASb) prior to randomization.

• Concomitant coronary artery bypass graft or other valvular intervention

• Other significant left-sided valvular heart diseases (=moderate), even without concomitant procedure

• Any contra-indication to CMR

• Chronic kidney disease with estimated glomerular filtration rate (GFR) <30 ml/min

• Prior or planned organ transplantation

• Hyperkaliemia (kaliemia >5.5 mmol/L at inclusion visit)

• Severe hepatic failure, biliary cirrhosis, cholestasis

• Combined use of aliskiren and concomitant diabetes mellitus or renal failure with GFR<60mL/min/1.73m²

• Low systolic blood pressure (<100mmHg)

• History of angioedema

• History of hypersensitivity or allergy to Angiotensin-II Receptor Blockers or excipient

• Under legal authority.

• Unwilling to consent

Secondary Exclusion Criteria:

• Patients not under RAASb prior to randomization but who should benefit from this treatment to improve outcome:

• Heart failure with reduced ejection fraction (<40%)

• Coronary artery disease

• Clinical peripheral artery disease

• History of cerebrovascular disease

• Uncontrolled hypertension despite the use of other therapeutic classes

• Diabetes mellitus

• Impossibility to perform randomization into the 9-day post-intervention period due to per procedural complication with prolonged stay in intensive cardiac care unit (including death).

Related Conditions & MeSH terms

• Angiotensin Receptor Antagonists
• Aortic Valve Stenosis
• Constriction, Pathologic
• Heart Valve Prosthesis Implantation
• Hypertrophy
• Hypertrophy, Left Ventricular
• Transcatheter Aortic Valve Replacement
• Valsartan

Intervention

Drug:
• Valsartan
The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
• Placebo Oral Tablet
The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.

Locations

Country	Name	City	State
France	Limoges university hospital	Limoges

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Indexed left ventricular mass	the 1-year change from baseline in indexed LVM after aortic valve intervention as assessed using cardiac magnetic resonance (CMR)	Day 0 to Year 1
Secondary	Left ventricular global longitudinal strain	The 1-year change from baseline in left ventricular global longitudinal strain quantified using CMR	Day 0 to Year 1
Secondary	Left ventricular global longitudinal strain	The 1-year change from baseline in Left ventricular global longitudinal strain quantified using transthoracic echocardiography (TTE)	Day 0 to Year 1
Secondary	Left atrial volume	The 1-year change from baseline in Left atrial volume quantified using CMR	Day 0 to Year 1
Secondary	Left atrial volume	The 1-year change from baseline in Left atrial volume quantified using TTE	Day 0 to Year 1
Secondary	Indexed left ventricular mass	the 1-year change from baseline in indexed LVM after aortic valve intervention as assessed using TTE (real-time 3D)	Day 0 to Year 1
Secondary	Native T1	the 1-year change from baseline in native T1 using CMR	Day 0 to Year 1
Secondary	Rate of late gadolinium enhancement (LGE)	the 1-year change from baseline in rate of LGE using CMR	Day 0 to Year 1
Secondary	Volume of late gadolinium enhancement (LGE)	the 1-year change from baseline in volume of LGE using CMR	Day 0 to Year 1
Secondary	Extra cellular volume	The 1-year change from baseline in extra cellular volume using CMR	Day 0 to Year 1
Secondary	Indexed interstitial volume	The 1-year change from baseline in Indexed interstitial volume using CMR	Day 0 to Year 1
Secondary	Electrocardiographic strain	The 1-year change from baseline in Electrocardiographic strain	Day 0 to Year 1
Secondary	Left ventricular ejection fraction	The 1-year change from baseline in Left ventricular ejection fraction using CMR	Day 0 to Year 1
Secondary	Left ventricular ejection fraction	The 1-year change from baseline in Left ventricular ejection fraction using TTE	Day 0 to Year 1
Secondary	Peak exercise VO2	The 1-year measurement of Peak exercise VO2	Year 1
Secondary	VE/VCO2 ratio	The 1-year measurement of VE/VCO2 ratio	1 year
Secondary	Maximal load	The 1-year maximal load reached	1 year
Secondary	New-York heart association functional class	The 1-year assessment of New-York heart association functional class	1 year
Secondary	Exercise oscillatory ventilation rate	The 1-year quantification of exercise oscillatory ventilation rate	1 year
Secondary	Nt-pro Brain natriuretic peptide	The 1-year change from baseline in level of Nt-pro Brain natriuretic peptide using immunoassay	Day 0 to Year 1
Secondary	Plasma cardiac troponin I	The 1-year change from baseline in concentration of Plasma cardiac troponin I using high-sensitivity assay	Day 0 to Year 1
Secondary	Incidence of treatment-Emergent Adverse Events	Clinical occurrence of adverse events (AEs) and serious adverse events (SAEs) during the duration of the study period ending month 13	Day 1 to Month 13